Atherosclerosis in systemic lupus erythematosus;Athérosclérose au cours du lupus érythémateux systémique

Presse Medicale

Volumn 43, Issue 10, 2014, Pages 1034-1047

  Tazi Mezalek, Zoubida ^a,b   Harmouche, Hicham ^a,b   Ammouri, Wafaa ^a,b   Maamar, Mouna ^a,b   Adnaoui, Mohamed ^a,b   Cacoub, Patrice ^c  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; TRIACYLGLYCEROL;

ADULT; ANTIGEN ANTIBODY COMPLEX; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CORONARY ARTERY CALCIFICATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HEART INFARCTION; HEART PROTECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIMARY PREVENTION; RESPONSIBILITY; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; CARDIOVASCULAR DISEASES; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREVALENCE; RISK FACTORS;

EID: 84908136864     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.01.021     Document Type: Article

References (134)

1. Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006, 119:1497-1499.
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000patients. Medicine 2003, 82:299-308.
3. Abu-Shakra M., Urowitz M.B., Gladman D.D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I.Causes of death. J Rheumatol 1995, 22:1259-1264.
4. Ward M.M., Pyun E., Studenski S. Causes of death in systemic lupus erythematosus. Arthritis Rheum 1995, 38:1492-1499.
5. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
6. Bjornadal L., Yin L., Granath F., Klareskog L., Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004, 31:713-719.
7. Urowitz M.B., Bookman A.A.M., Koehler B.E., Gordon D.A., Smuthe H.A., Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60:221-225.
8. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
9. Bessant R., Duncan R., Ambler G., Swanton J., Isenberg D.A., Gordon C., et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006, 55:892-899.
10. Petri M., Perez-Gutthann S., Spence D., Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93:513-519.
11. Urowitz M.B., Gladman D., Ibañez D., Bae S.C., Sanchez-Guerrero J., Gordon C., et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res 2010, 62:881-887.
12. Magder L.S., Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012, 176:708-719.
13. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975, 58:243-264.
14. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997, 145:408-415.
15. Hak A.E., Karlson E.W., Feskanich D., Stampfer M.J., Costenbader K.H. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study. Arthritis Rheum 2009, 61:1396-1402.
16. Kao A.H., Lertratanakul A., Elliott J.R., Sattar A., Santelices L., Shaw P., et al. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013, 112:1025-1032.
17. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51-60.
18. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
19. Selzer F., Sutton-Tyrrell K., Fidgerald S.G., Pratt J.E., Tracy R.P., Kuller L.H., et al. Comparison of risk factors for vascular disease in the carotid artery an aorta in woman with systemic lupus erythematosus. Arthritis Rheum 2004, 50:151-159.
20. Ahmad Y., Shelmerdine J., Bodill H., Lunt M., Pattrick M.G., Teh L.S., et al. Subclinical atherosclerosis in systemic lupus erythematosus: the relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007, 46:983-988.
21. Doria A., Shoenfeld Y., Wu R., Gambari P.F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071-1077.
22. Thompson T., Sutton-Tyrrel K., Wildman R.P., Kao A., Fitzgerald S.G., Shook B., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008, 58:835-842.
23. Jimenez S., Garcia-Criado M.A., Tassies D., Reverter J.C., Cervera R., Gilabert M.R., et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005, 44:756-761.
24. Roman M.J., Crow M.K., Lockshin M.D., Devereux R.B., Paget S.A., Sammaritano L., et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412-3419.
25. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
26. Manger K., Kusus M., Forster C., Ropers D., Daniel W.G., Kalden J.R., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003, 62:846-850.
27. Von Feldt J.M., Scalzi L.V., Cucchiara A.J., Morthala S., Kealey C., Flagg S.D., et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:220-227.
28. Kiani A., Magder L., Petri M. Coronary calcium in systemic lupus erthematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35:1300-1306.
29. Theodoridou A., Bento L., D'Cruz D.P., Khamashta M.A., Hughes G.R. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis 2003, 62:1199-1203.
30. Sella E.M., Sato E.I., Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 2003, 48:3168-3175.
31. El Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110:399-404.
32. Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmunity 2006, 27:211-217.
33. Goldberg R.J., Urowitz M.B., Ibanez D., Nipkour M., Gladman D.D. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. Rheumatology 2009, 36:2454-2461.
34. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus 2000, 9:170-175.
35. Vlachoyiannopoulos P.G., Kanellopoulos P.G., Ioannidis J.P.A., Tektonidou M.G., Mastorakou I., Moutsopoulos H.M. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 2003, 42:645-651.
36. Bruce I.N., Urowitz M.B., Gladman D.D., Ibanez D., Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. Arthritis Rheum 2003, 48:3159-3167.
37. Urowitz M.B., Ibañez D., Gladman D.D. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007, 34:70-75.
38. Haque S., Gordon C., Isenberg D., Rahman A., Lanyon P., Bell A., et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010, 37:322-329.
39. Rahman P., Urowitz M.B., Gladman D.D., Bruce I.N., Genest J. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999, 26:2363-2368.
40. Toloza S.M., Uribe A.G., McGwin G., Alarcon G.S., Fessler B.J., Bastian H.M., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957.
41. Marasini B., De Monti M., Ghilardi G. Risk factors for accelerated atherosclerosis in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:163-164.
42. Powell C., Brown E.E.on behaf of PROFILE, McGwin G., Vila L.M., Santiago-Casas Y.C., Petri M., et al. Differences in the SLE clinical phenotype by age of diagnosis. Arthritis Rheum 2012, 64:S289.
43. Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997, 6:533-539.
44. Formiga F., Meco J.F., Pinto X., Jacob J., Moga I., Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001, 10:359-363.
45. Ilowite N.T., Samuel P., Ginzler E., Jacobson M.S. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988, 31:859-863.
46. Sarkissian T., Beyenne J., Feldman B., Adeli K., Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 2006, 54:1283-1290.
47. Svenungsson E., Gunnarsson I., Fei G.Z., Lundberg I.E., Klareskog L., Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2533-2540.
48. Chung C.P., Oeser A., Solus J., Avalos I., Gebretsadik T., Shintani A., et al. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 2007, 34:1849-1854.
49. Bruce I.N., Urowitz M.B., Gladman D.D., Hallett D.C. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137-2143.
50. Urowitz M.B., Gladman D., Ibanez D., Fortin P., Sanchez-Guerrero J., Bae S., et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007, 16:731-735.
51. Touma Z., Gladman D.D., Ibanez D., Urowitz M.B. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology 2012, 513:528-534.
52. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.A., Maranhão R.C. Chylomicrons metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1033-1040.
53. Reichlin M., Fesmire J., Quintero-Del-Rio A.I., Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2957-2963.
54. Van Lenten B.J., Reddy S.T., Navab M., Fogelman A.M. Understanding changes in hight-density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006, 26:1806-1813.
55. McMahon M., Grossman J., Fitzgerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory hight-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rhumatoid arthritis. Arthritis Rheum 2006, 54:2541-2549.
56. Dinu A.R., Merrill J.T., Sutton-Tyrell K. Autoantibodies to apolipoprotein A1 (APOA1) in an SLE population: relationship to HDL levels and to carotid atherosclerosis by ultrasound assessment. Arthritis Rheum 1998, 41:S139.
57. McMahon M., Grossman J., Fitzgerald J. The novel biomarker proinlfammatory HDL is associated with carotid artery plaque in women with SLE. Arhritis Rheum 2006, 54:S522.
58. Missala I., Kassner U., Steinhagen-Thiessen E. A systematic literature review of the association of Lipoprotein(a) and autoimmune diseases and atherosclerosis. Int J Rheumatol 2012, 2012:480784.
59. El Magdami M., Ahmed Y., Turkic W., Yates A.P., Sheikh N., Bernstein R.M., et al. Hyperinsulinemia, insulin resistance and circulating oxidised low-density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006, 33:50-56.
60. Chung C.P., Avalos I., Oeser A., Gebretsadik T., Shintani A., Raggi P., et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007, 66:208-214.
61. Sabio J.M., Zamora-Pasadas M., Jiménez-Jáimez J., Albadalejo F., Vargas-Hitos J., Rodríguez del Águila M.D.M., et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008, 17:849-859.
62. Parker B., Urowitz M.B., Gladman D.D., Lunt M., Bae S.C., Sanchez-Guerrero J., et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013, 72:1308-1314.
63. Gustafsson J., Gunnarsson I., Borjesson O., Pettersson S., Moller S., Fei G.Z., et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus: a prospective cohort study. Arthritis Res Ther 2009, 116:R186.
64. Ghaussy N.O., Sibbitt W., Bankhurst A.D., Qualls C.R. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003, 30:1215-1221.
65. Rahman P., Gladman D.D., Urowitz M.B. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998, 25:1716-1719.
66. Petri M., Rubenoff R., Dallal G.E., Nadeau M.R., Selhub J., Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996, 348:1120-1124.
67. Volkmann E.R., Grossman J.M., Sahakian L.J., Skaggs B.J., FitzGerald J., Ragavendra N., et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 2010, 62:258-265.
68. Ibanez D., Gladman D.D., Urowitz M.B. Adjusted mean SLEDAI-2K (AMS) in outcome prediction in SLE. Arthritis Rheum 2004, 50(Suppl.9):S199.
69. Lopez R., Davidson J.E., Beeby M.D., Egger P.J., Isenberg D.A. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012, 51:491-498.
70. Font J., Ramos-Casals M., Cervera R., García-Carrasco M., Torras A., Sisó A., et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001, 94:19-26.
71. Leong K.H., Koh E.T., Feng P.H., Boey M.L. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994, 21:1264-1267.
72. Tyrrel P.N., Beyenne J., Benseler S.M., Sarkissian T., Silverman E.D. Predictors of lipid abnormalities in children with new onset systemic lupus erythematosus. J Rheumatol 2007, 34:2112-2118.
73. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of pro-atherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006, 33:539-545.
74. McMahon M., Grossman J., Chen W., Hahn B.H. Inflammation and pathogenesis of atherosclerosis in systemic lupus erythematosus. Lupus 2006, 15:59-69.
75. Barnes E.V., Narain S., Naranjo A., Shuster J., Segal M.S., Sobel E.S., et al. Hight sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005, 14:576-582.
76. Mok C.C., Birmingham D.J., Ho L.Y., Hebert L.A., Rovin B.H. High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 2013, 65:441-447.
77. Lee P.Y., Li Y., Richards H.B., Chan F.S., Zhuang H., Narain S., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3759-3769.
78. Jia Li J., Qiong Fu O., Huijuan Cui H., Bo Qu B., Wen Pan W., Nan Shen N., et al. Interferon-∝ priming promotes lipid uptake and macrophage-derived foam cell formation. A novel link between Interferon-∝ and atherosclerosis in lupus. Arthritis Rheum 2011, 63:492-502.
79. Liang K.P., Kremers H.M., Crowson C.S., Snyder M.R., Therneau T.M., Roger V.L., et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2469.
80. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of β2 glycoprotein I (apolipoprotein H) to human atheroscerotic plaques. Potential implications for lesion progression. Circulation 1999, 99:2227-2230.
81. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of β2 glycoprotein I and anticardiolipin antibodies inoxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573.
82. George J., Afek A., Gilburd B., Blank M., Levy Y., Aron-Maor A., et al. Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta2-glycoprotein I. Circulation 1998, 98:1108-1115.
83. Lambert M., Boullier A., Hachulla E., Fruchart J.C., Teissier E., Hatron P.Y., et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000, 9:299-300.
84. Meroni P.L., Raschi E., Testoni C., Borghi M.O. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169-174.
85. Cederholm A., Svenungsson E., Jensen-Urstad K., Trollmo C., Ulfgren A.K., Swedenborg J., et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005, 25:198-203.
86. Svenungsson E., Jensen-Urstad K., Heimbürger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887-1893.
87. Nojima J., Masuda Y., Iwatani Y., Kuratsune H., Watanabe Y., Suehisa E., et al. Arteriosclerosis obliterans associated with anticardiolipin antibody/β2-glycoprotein I antibodies as a strong risk factor for ischemic heart disease in patients with systemic lupus erythematosus. Rheumatology 2008, 47:684-689.
88. Medina G., Casaos D., Jara L.J., Vera-Lastra O., Fuentes M., Barile L. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003, 62:607-610.
89. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004, 114:593-595.
90. Hayem G., Nicaise Roland P., Palazzo E., De Bandt M., Tubach F., Weber M., et al. Anti-oxidized low-density lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001, 10:346-351.
91. Bassi N., Ghirardello A., Iaccarino L., Zampieri S., Rampudda M.E., Atzeni F., et al. OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 2007, 7:52-58.
92. Lopez L.R., Simpson D.F., Hurley B.L., Matsuura E. OxLDL/β2GPI complexes and antibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 2005, 1051:313-322.
93. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., Hurley B.L., Matsuura E., Garcia De La Torre I. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thikness: implications in autoimmune-mediated atherosclerosis. Lupus 2006, 15:80-86.
94. Dieude M., Senecal J.L., Raymond Y. Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell antibody-positive systemic lupus erythematosus patients. Arthritis Rheum 2004, 50:3221-3231.
95. Navarro M., Cervera R., Font J., Reverter J.C., Monteagudo J., Escolar G., et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997, 6:521-526.
96. Carvalho D., Savage C.O., Isenberg D., Pearson J.D. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leucocyte adhesion in an autocine manner. Arthritis Rheum 1999, 42:631-640.
97. Hansson G.K., Libby P., Schönbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281-291.
98. Reiss A.B., Malhotra S., Javitt N.B., Grossi E.A., Galloway A.C., Montesinos M.C., et al. Occupancy of C1q receptors on endothelial cells (EC) by immune complexes downregulates mRNA for sterol 27-hydroxylase (27-OH'ase), the major mediator of extra-hepatic cholesterol metabolism [abstract]. Arthritis Rheum 1998, 41:79.
99. Rua-Figueroa I., Arencibia-Mireles O., Elvira M., Erausquin C., Ojeda S., Francisco F., et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010, 69:1136-1139.
100. Nuttall S.L., Heaton S., Piper M.K., Martin U., Gordon C. Cardiovascular risk in systemic lupus erythematosus-evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003, 42:758-762.
101. Kiani A.N., Mahoney J.A., Petri M. Asymmetric dimethylarginine is a marker of a poor prognosis and coronary calcium in systemic lupus erythematosus. J Rheumatol 2007, 34:1502-1505.
102. Bultink I.E., Teerlink T., Heijst J.A., Dijkmans B.A., Voskuyl A.E. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1362-1365.
103. Szwebel T.A., Le Jeunne C. Risques cardiovasculaires d'une corticothérapie. Presse Med 2012, 41:384-392.
104. Petri M., Lakatta C., Magder L., Goldman D.W. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259.
105. Zonana-Nacach A., Barr S.G., Laurence S.M., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43:1801-1808.
106. Karp I., Abrahamowicz M., Fortin P.R., Pilote L., Neville C., Pineau C.A., et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus. Arthritis Rheum 2008, 59:169-175.
107. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
108. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
109. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., Bruce I.N. The cholesterol-lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325-330.
110. Borba E.F., Bonfa E. Long-term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001, 28:780-785.
111. Wallace D.J., Metzger A.L., Steicher V.J., Turnbull B.A., Kern P.A. The cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322-326.
112. Petri M., Yoo S.S. Predictors of glucose intolerance in systemic lupus erythematosus. Arthritis Rheum 1994, 37:S323.
113. Wasko M.C., Hubert H.B., Lingala V.B., Elliott J.R., Luggen M.E., Fries J.F., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298:187-193.
114. Van Leuven S.I., Mendez-Fernandez Y.V., Wilhelm A.J., Wade N.S., Gabriel C.L., Kastelein J.J., et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis 2012, 71:408-414.
115. Pego-Reigosa J.M., Lu T.Y., Fontanillo M.F., del Campo-Pérez V., Rahman A., Isenberg D.A. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology 2010, 49:691-696.
116. Bruce I.N., Gladman D.D., Urowitz M.B. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998, 16:435-440.
117. Al Herz A., Ensworth S., Shojania K., Esdaile J.M. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 2003, 30:493-496.
118. Costenbader K.H., Wright E., Liang M.H., Karlson E.W. Cardiac risk factor awereness and management in patients with systemic lupus erythematosus. Arthritis Rheum 2004, 66:2017-2021.
119. Scalzi L.V., Ballou S.P., Park J.Y., Redline S., Kirchner H.L. Cardiovascular disease risk awareness in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:1458-1464.
120. Petri M., Spence D., Bone L.R., et al. Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence, recognition by patients, and preventative practices. Medecine 1992, 71:291-302.
121. Urowitz M.B., Gladman D.D., Ibanez D., Berliner Y. Modification of hypertension and hypercholesterolemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 2006, 65:115-117.
122. Wajed J., Ahmad Y., Durrington P.N., Bruce I.N. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology 2004, 43:7-12.
123. Bruce I.N. 'Not only. . . but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005, 44:1492-1502.
124. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
125. Lawman S., Ehrenstein M. Atorvastatin reduces MHC class II expression and ameliorates autoimmunity in the NZB/W mouse model of lupus. Arthritis Rheum 2003, 48(Suppl. 1):S200.
126. Petri M.A., Kiani A.N., Post W., Christopher-Stine L., Magder L.S. Extended report: Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011, 70:760-765.
127. Schanberg L.E., Sandborg C., Barnhart H.X., Ardoin S.P., Yow E., Evans G.W., et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012, 64:285-296.
128. Ardoin S.P., Schanberg L.E., Sandborg C.I., Barnhart H.X., Evans G.W., Yow E., et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C-reactive protein. Ann Rheum Dis 2014, 73:557-566.
129. Mok C.C., Wong C.K., To C.H., Lai J.P., Lam C.S. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011, 63:875-883.
130. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
131. Taylor F., Huffman M.D., Macedo A.F., Moore T.H.M., Burke M., Davey Smith G., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Syst Rev 2013, 1:CD004816.
132. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005, 352:1293-1304.
133. Leung M.H., Heaton S., Skan J. Mortality and malignancy in the multiethnic Birmingham Lupus Cohort-aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome. Rheumatology 2002, 41(Suppl. 1):S17.
134. Wahl D.G., Bounameaux H., de Moerloose P., Sarasin F.P. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Int Med 2000, 160:2042-2048.